Drug intelligence / Profile preview

Jiajian Yishen Xiaozheng Qufeng Granules

Development stage: Preclinical
Lead developer: Jiazhen Yin
Modality: Small Molecules
Administration: Oral

Overview

Jiajian Yishen Xiaozheng Qufeng Granules is an investigational Traditional Chinese Medicine (TCM) formulation developed for the treatment of diabetic nephropathy (DKD). The formula is designed to improve remission rates and delay disease progression in patients with type 2 diabetic nephropathy by potentially reducing proteinuria and protecting renal function. It is currently being evaluated in multicenter, prospective, double-blind, randomized, placebo-controlled clinical trials as an adjunct to standard basic treatments. The granules are manufactured by Jiangyin Tianjiang Pharmaceutical and the research initiative is led by Jiazhen Yin.

Other names: Jia Jian Yi Shen Xiao Zheng Qu Feng Fang GranulesJiade Yishen Xiaozheng Qufang

Beyond the preview

Go deeper on Jiajian Yishen Xiaozheng Qufeng Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jiajian Yishen Xiaozheng Qufeng Granules.

Explore the full profile